Privo Technologies

Privo Technologies is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of debilitating and potentially fatal mucosal cancer. Privo is developing a novel, nanotechnology-based drug delivery platform capable of delivering constant and controlled therapeutic doses both locally to the mucosa and systemically. This approach eliminates the need for needles, avoids stomach acid, can significantly reduce toxic side effects of medications, and allows for higher doses to be administered where the drug is most effective. All of these factors improve patient outcomes and compliance. PRV111 is an innovative transmucosal drug delivery system that enables localized direct administration (cisplatin) to the tumor site. The data from this trial supports the company’s mission since its inception: to optimize state-of-the-art chemotherapy drugs to be "more effective against cancer and easier on patients."